vs
CRYO CELL INTERNATIONAL INC（CCEL）与Sotera Health Co（SHC）财务数据对比。点击上方公司名可切换其他公司
Sotera Health Co的季度营收约是CRYO CELL INTERNATIONAL INC的38.7倍（$303.4M vs $7.8M）。Sotera Health Co净利率更高（11.5% vs -48.7%，领先60.2%）。Sotera Health Co同比增速更快（4.6% vs -2.3%）。Sotera Health Co自由现金流更多（$52.4M vs $1.2M）。过去两年Sotera Health Co的营收复合增速更高（10.6% vs -0.1%）
Cryo-Cell国际是一家脐带血库企业，由丹·理查德于1989年创立，是全球首家分离并储存干细胞的民营脐带血库，总部位于佛罗里达州奥兹马尔，地处坦帕市郊。
Sotera Health Co是全球领先的医疗安全解决方案提供商，面向医疗器械厂商、制药企业、食品及消费品公司提供灭菌服务、实验室分析检测与合规咨询支持，帮助客户满足监管要求，保障上市产品的使用安全。
CCEL vs SHC — 直观对比
营收规模更大
SHC
是对方的38.7倍
$7.8M
营收增速更快
SHC
高出6.8%
-2.3%
净利率更高
SHC
高出60.2%
-48.7%
自由现金流更多
SHC
多$51.2M
$1.2M
两年增速更快
SHC
近两年复合增速
-0.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $7.8M | $303.4M |
| 净利润 | $-3.8M | $34.8M |
| 毛利率 | 77.9% | 54.7% |
| 营业利润率 | -50.6% | 23.2% |
| 净利率 | -48.7% | 11.5% |
| 营收同比 | -2.3% | 4.6% |
| 净利润同比 | -105.1% | 182.8% |
| 每股收益（稀释后） | $-0.46 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCELSHC
| Q4 25 | $7.8M | $303.4M | ||
| Q3 25 | $7.8M | $311.3M | ||
| Q2 25 | $7.9M | $294.3M | ||
| Q1 25 | $8.0M | $254.5M | ||
| Q4 24 | $8.0M | $290.2M | ||
| Q3 24 | $8.1M | $285.5M | ||
| Q2 24 | $8.0M | $276.6M | ||
| Q1 24 | $7.9M | $248.2M |
净利润CCELSHC
| Q4 25 | $-3.8M | $34.8M | ||
| Q3 25 | $749.4K | $48.4M | ||
| Q2 25 | $355.8K | $8.0M | ||
| Q1 25 | $282.9K | $-13.3M | ||
| Q4 24 | $-1.9M | $12.3M | ||
| Q3 24 | $1.1M | $17.0M | ||
| Q2 24 | $655.8K | $8.8M | ||
| Q1 24 | $556.2K | $6.3M |
毛利率CCELSHC
| Q4 25 | 77.9% | 54.7% | ||
| Q3 25 | 77.0% | 57.0% | ||
| Q2 25 | 76.6% | 56.6% | ||
| Q1 25 | 75.1% | 53.2% | ||
| Q4 24 | 78.4% | 56.6% | ||
| Q3 24 | 73.6% | 55.4% | ||
| Q2 24 | 74.8% | 55.2% | ||
| Q1 24 | 73.7% | 51.2% |
营业利润率CCELSHC
| Q4 25 | -50.6% | 23.2% | ||
| Q3 25 | 24.3% | 23.4% | ||
| Q2 25 | 18.8% | 6.4% | ||
| Q1 25 | 13.3% | -5.8% | ||
| Q4 24 | -1.5% | 30.0% | ||
| Q3 24 | 17.2% | 28.2% | ||
| Q2 24 | 17.3% | 27.8% | ||
| Q1 24 | 10.5% | 21.4% |
净利率CCELSHC
| Q4 25 | -48.7% | 11.5% | ||
| Q3 25 | 9.6% | 15.5% | ||
| Q2 25 | 4.5% | 2.7% | ||
| Q1 25 | 3.5% | -5.2% | ||
| Q4 24 | -23.2% | 4.2% | ||
| Q3 24 | 13.0% | 6.0% | ||
| Q2 24 | 8.2% | 3.2% | ||
| Q1 24 | 7.1% | 2.5% |
每股收益（稀释后）CCELSHC
| Q4 25 | $-0.46 | $0.12 | ||
| Q3 25 | $0.09 | $0.17 | ||
| Q2 25 | $0.04 | $0.03 | ||
| Q1 25 | $0.03 | $-0.05 | ||
| Q4 24 | $-0.23 | $0.05 | ||
| Q3 24 | $0.13 | $0.06 | ||
| Q2 24 | $0.08 | $0.03 | ||
| Q1 24 | $0.07 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.3M | $344.6M |
| 总债务越低越好 | $8.4M | $2.1B |
| 股东权益账面价值 | $-18.6M | $606.0M |
| 总资产 | $61.7M | $3.3B |
| 负债/权益比越低杠杆越低 | — | 3.53× |
8季度趋势，按日历期对齐
现金及短期投资CCELSHC
| Q4 25 | $3.3M | $344.6M | ||
| Q3 25 | $3.2M | $299.2M | ||
| Q2 25 | $4.4M | $332.4M | ||
| Q1 25 | $3.5M | $304.4M | ||
| Q4 24 | $3.5M | $277.2M | ||
| Q3 24 | $2.1M | $306.7M | ||
| Q2 24 | $1.5M | $246.1M | ||
| Q1 24 | $979.6K | $261.1M |
总债务CCELSHC
| Q4 25 | $8.4M | $2.1B | ||
| Q3 25 | $8.4M | $2.1B | ||
| Q2 25 | $8.4M | $2.2B | ||
| Q1 25 | $8.5M | $2.2B | ||
| Q4 24 | $8.5M | $2.2B | ||
| Q3 24 | $8.5M | $2.2B | ||
| Q2 24 | $8.5M | $2.2B | ||
| Q1 24 | $8.6M | $2.2B |
股东权益CCELSHC
| Q4 25 | $-18.6M | $606.0M | ||
| Q3 25 | $-14.8M | $550.5M | ||
| Q2 25 | $-15.6M | $511.3M | ||
| Q1 25 | $-14.7M | $414.1M | ||
| Q4 24 | $-13.2M | $404.9M | ||
| Q3 24 | $-9.6M | $470.2M | ||
| Q2 24 | $-10.7M | $422.8M | ||
| Q1 24 | $-10.3M | $429.4M |
总资产CCELSHC
| Q4 25 | $61.7M | $3.3B | ||
| Q3 25 | $63.2M | $3.2B | ||
| Q2 25 | $64.4M | $3.2B | ||
| Q1 25 | $64.4M | $3.1B | ||
| Q4 24 | $64.7M | $3.1B | ||
| Q3 24 | $62.9M | $3.1B | ||
| Q2 24 | $62.6M | $3.1B | ||
| Q1 24 | $61.7M | $3.1B |
负债/权益比CCELSHC
| Q4 25 | — | 3.53× | ||
| Q3 25 | — | 3.89× | ||
| Q2 25 | — | 4.34× | ||
| Q1 25 | — | 5.36× | ||
| Q4 24 | — | 5.49× | ||
| Q3 24 | — | 4.73× | ||
| Q2 24 | — | 5.26× | ||
| Q1 24 | — | 5.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3M | $103.1M |
| 自由现金流经营现金流 - 资本支出 | $1.2M | $52.4M |
| 自由现金流率自由现金流/营收 | 15.5% | 17.3% |
| 资本支出强度资本支出/营收 | 0.9% | 16.7% |
| 现金转化率经营现金流/净利润 | — | 2.96× |
| 过去12个月自由现金流最近4个季度 | $5.2M | $149.2M |
8季度趋势，按日历期对齐
经营现金流CCELSHC
| Q4 25 | $1.3M | $103.1M | ||
| Q3 25 | $2.5M | $71.2M | ||
| Q2 25 | $707.0K | $57.4M | ||
| Q1 25 | $954.1K | $55.5M | ||
| Q4 24 | $2.2M | $55.7M | ||
| Q3 24 | $2.4M | $97.5M | ||
| Q2 24 | $1.8M | $61.3M | ||
| Q1 24 | $-356.9K | $9.7M |
自由现金流CCELSHC
| Q4 25 | $1.2M | $52.4M | ||
| Q3 25 | $2.5M | $35.0M | ||
| Q2 25 | $644.6K | $26.2M | ||
| Q1 25 | $892.0K | $35.6M | ||
| Q4 24 | $2.1M | $-10.2M | ||
| Q3 24 | $2.3M | $61.1M | ||
| Q2 24 | $21.5K | $19.4M | ||
| Q1 24 | $-814.6K | $-25.2M |
自由现金流率CCELSHC
| Q4 25 | 15.5% | 17.3% | ||
| Q3 25 | 31.9% | 11.2% | ||
| Q2 25 | 8.1% | 8.9% | ||
| Q1 25 | 11.2% | 14.0% | ||
| Q4 24 | 26.8% | -3.5% | ||
| Q3 24 | 27.9% | 21.4% | ||
| Q2 24 | 0.3% | 7.0% | ||
| Q1 24 | -10.4% | -10.2% |
资本支出强度CCELSHC
| Q4 25 | 0.9% | 16.7% | ||
| Q3 25 | 0.5% | 11.6% | ||
| Q2 25 | 0.8% | 10.6% | ||
| Q1 25 | 0.8% | 7.8% | ||
| Q4 24 | 0.1% | 22.7% | ||
| Q3 24 | 2.3% | 12.7% | ||
| Q2 24 | 21.8% | 15.2% | ||
| Q1 24 | 5.8% | 14.1% |
现金转化率CCELSHC
| Q4 25 | — | 2.96× | ||
| Q3 25 | 3.38× | 1.47× | ||
| Q2 25 | 1.99× | 7.21× | ||
| Q1 25 | 3.37× | — | ||
| Q4 24 | — | 4.52× | ||
| Q3 24 | 2.32× | 5.73× | ||
| Q2 24 | 2.70× | 7.00× | ||
| Q1 24 | -0.64× | 1.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCEL
暂无分部数据
SHC
| Transferred At Point In Time | $198.4M | 65% |
| Nelson Labs | $55.2M | 18% |
| Nordion | $49.8M | 16% |
